FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3193435367> ?p ?o ?g. }

• W3193435367 endingPage "1257" @default.
• W3193435367 startingPage "1257" @default.
• W3193435367 abstract "<h3>Importance</h3> The density of atherosclerotic plaque forms the basis for categorizing calcified and noncalcified morphology of plaques. <h3>Objective</h3> To assess whether alterations in plaque across a range of density measurements provide a more detailed understanding of atherosclerotic disease progression. <h3>Design, Setting, and Participants</h3> This cohort study enrolled 857 patients who underwent serial coronary computed tomography angiography 2 or more years apart and had quantitative measurements of coronary plaques throughout the entire coronary artery tree. The study was conducted from 2013 to 2016 at 13 sites in 7 countries. <h3>Main Outcomes and Measures</h3> The main outcome was progression of plaque composition of individual coronary plaques. Six plaque composition types were defined on a voxel-level basis according to the plaque attenuation (expressed in Hounsfield units [HU]): low attenuation (−30 to 75 HU), fibro-fatty (76-130 HU), fibrous (131-350 HU), low-density calcium (351-700 HU), high-density calcium (701-1000 HU), and 1K (>1000 HU). The progression rates of these 6 compositional plaque types were evaluated according to the interaction between statin use and baseline plaque volume, adjusted for risk factors and time interval between scans. Plaque progression was also examined based on baseline calcium density. Analysis was performed among lesions matched at baseline and follow-up. Data analyses were conducted from August 2019 through March 2020. <h3>Results</h3> In total, 2458 coronary lesions in 857 patients (mean [SD] age, 62.1 [8.7] years; 540 [63.0%] men; 548 [63.9%] received statin therapy) were included. Untreated coronary lesions increased in volume over time for all 6 compositional types. Statin therapy was associated with volume decreases in low-attenuation plaque (β, −0.02; 95% CI, −0.03 to −0.01;<i>P</i> = .001) and fibro-fatty plaque (β, −0.03; 95% CI, −0.04 to −0.02;<i>P</i> < .001) and greater progression of high-density calcium plaque (β, 0.02; 95% CI, 0.01-0.03;<i>P</i> < .001) and 1K plaque (β, 0.02; 95% CI, 0.01-0.03;<i>P</i> < .001). When analyses were restricted to lesions without low-attenuation plaque or fibro-fatty plaque at baseline, statin therapy was not associated with a change in overall calcified plaque volume (β, −0.03; 95% CI, −0.08 to 0.02;<i>P</i> = .24) but was associated with a transformation toward more dense calcium. Interaction analysis between baseline plaque volume and calcium density showed that more dense coronary calcium was associated with less plaque progression. <h3>Conclusions and Relevance</h3> The results suggest an association of statin use with greater rates of transformation of coronary atherosclerosis toward high-density calcium. A pattern of slower overall plaque progression was observed with increasing density. All findings support the concept of reduced atherosclerotic risk with increased densification of calcium." @default.
• W3193435367 created "2021-08-30" @default.
• W3193435367 creator A5000029547 @default.
• W3193435367 creator A5000568658 @default.
• W3193435367 creator A5002948405 @default.
• W3193435367 creator A5007158625 @default.
• W3193435367 creator A5010266887 @default.
• W3193435367 creator A5011690197 @default.
• W3193435367 creator A5012676647 @default.
• W3193435367 creator A5014445990 @default.
• W3193435367 creator A5015575116 @default.
• W3193435367 creator A5015837130 @default.
• W3193435367 creator A5017123962 @default.
• W3193435367 creator A5020936555 @default.
• W3193435367 creator A5021252270 @default.
• W3193435367 creator A5022683161 @default.
• W3193435367 creator A5023253601 @default.
• W3193435367 creator A5023500198 @default.
• W3193435367 creator A5023566773 @default.
• W3193435367 creator A5026130256 @default.
• W3193435367 creator A5033386949 @default.
• W3193435367 creator A5035133412 @default.
• W3193435367 creator A5039146544 @default.
• W3193435367 creator A5039606590 @default.
• W3193435367 creator A5040287240 @default.
• W3193435367 creator A5048619815 @default.
• W3193435367 creator A5053011724 @default.
• W3193435367 creator A5054052272 @default.
• W3193435367 creator A5056485909 @default.
• W3193435367 creator A5062520509 @default.
• W3193435367 creator A5071199634 @default.
• W3193435367 creator A5071287538 @default.
• W3193435367 creator A5071379214 @default.
• W3193435367 creator A5073112520 @default.
• W3193435367 creator A5076641036 @default.
• W3193435367 creator A5077400642 @default.
• W3193435367 creator A5079476971 @default.
• W3193435367 creator A5079665496 @default.
• W3193435367 creator A5079958755 @default.
• W3193435367 creator A5085941737 @default.
• W3193435367 creator A5087665620 @default.
• W3193435367 date "2021-11-01" @default.
• W3193435367 modified "2023-10-18" @default.
• W3193435367 title "Association of Statin Treatment With Progression of Coronary Atherosclerotic Plaque Composition" @default.
• W3193435367 cites W2014951154 @default.
• W3193435367 cites W2065399536 @default.
• W3193435367 cites W2069557124 @default.
• W3193435367 cites W2090087329 @default.
• W3193435367 cites W2108234186 @default.
• W3193435367 cites W2121363804 @default.
• W3193435367 cites W2124658615 @default.
• W3193435367 cites W2127269137 @default.
• W3193435367 cites W2149953840 @default.
• W3193435367 cites W2160887646 @default.
• W3193435367 cites W2335455113 @default.
• W3193435367 cites W2530696279 @default.
• W3193435367 cites W2531870188 @default.
• W3193435367 cites W2558569891 @default.
• W3193435367 cites W2591646795 @default.
• W3193435367 cites W2611954277 @default.
• W3193435367 cites W2781614211 @default.
• W3193435367 cites W2804450541 @default.
• W3193435367 cites W2805117454 @default.
• W3193435367 cites W2900354984 @default.
• W3193435367 cites W2909165994 @default.
• W3193435367 cites W2915918168 @default.
• W3193435367 cites W3002167629 @default.
• W3193435367 cites W3004243791 @default.
• W3193435367 cites W3010781007 @default.
• W3193435367 doi "https://doi.org/10.1001/jamacardio.2021.3055" @default.
• W3193435367 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8374741" @default.
• W3193435367 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34406326" @default.
• W3193435367 hasPublicationYear "2021" @default.
• W3193435367 type Work @default.
• W3193435367 sameAs 3193435367 @default.
• W3193435367 citedByCount "54" @default.
• W3193435367 countsByYear W31934353672021 @default.
• W3193435367 countsByYear W31934353672022 @default.
• W3193435367 countsByYear W31934353672023 @default.
• W3193435367 crossrefType "journal-article" @default.
• W3193435367 hasAuthorship W3193435367A5000029547 @default.
• W3193435367 hasAuthorship W3193435367A5000568658 @default.
• W3193435367 hasAuthorship W3193435367A5002948405 @default.
• W3193435367 hasAuthorship W3193435367A5007158625 @default.
• W3193435367 hasAuthorship W3193435367A5010266887 @default.
• W3193435367 hasAuthorship W3193435367A5011690197 @default.
• W3193435367 hasAuthorship W3193435367A5012676647 @default.
• W3193435367 hasAuthorship W3193435367A5014445990 @default.
• W3193435367 hasAuthorship W3193435367A5015575116 @default.
• W3193435367 hasAuthorship W3193435367A5015837130 @default.
• W3193435367 hasAuthorship W3193435367A5017123962 @default.
• W3193435367 hasAuthorship W3193435367A5020936555 @default.
• W3193435367 hasAuthorship W3193435367A5021252270 @default.
• W3193435367 hasAuthorship W3193435367A5022683161 @default.
• W3193435367 hasAuthorship W3193435367A5023253601 @default.
• W3193435367 hasAuthorship W3193435367A5023500198 @default.
• W3193435367 hasAuthorship W3193435367A5023566773 @default.
• W3193435367 hasAuthorship W3193435367A5026130256 @default.

• next